SANIONA A/S - CVR: 34049610

2023, DKK

10.06.2024

Bruttoresultat

-20.526'

Primær drift

-47.482'

Årets resultat

-33.186'

Aktiver

97.740'

Kortfristede aktiver

85.022'

Egenkapital

84.303'

Afkastningsgrad

-49 %

Soliditetsgrad

86 %

Likviditetsgrad

+500%

Resultat

10.06.2024

Årsrapport	2023 10.06.2024	2022 26.05.2023	2021 03.06.2022	2020 06.07.2021	2019 12.05.2020	2018 30.05.2019	2017 29.05.2018	2016 04.05.2017	2015 18.05.2016
Nettoomsætning	11.198.265	9.931.778	19.987.709	5.818.910	1.890.378	39.537.696	16.005.672	58.855.825	10.873.673
Bruttoresultat	-20.526.362	0	0	0	0	0	-20.558.063	22.855.090	-8.257.382
Resultat af primær drift	-47.482.109	-69.585.948	-53.944.292	-79.433.433	-66.809.172	-34.190.368	-37.521.579	9.371.136	-20.770.555
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	9.718.510	0	0	0	0	0
Finansielle indtægter	10.914.628	9.840.726	303.900	24.015.289	1.712.892	2.318.678	980.172	132	0
Finansieringsomkostninger	-1.246.977	-9.832.687	-200.866.216	-48.332.549	-6.247.506	-1.469.947	0	0	0
Andre finansielle omkostninger	0	0	0	0	0	0	-941.920	-615.779	-647.476
Resultat før skat	-38.685.717	-153.026.770	-251.555.582	-94.032.183	-71.343.786	-33.341.637	-37.483.327	9.623.831	-21.418.031
Resultat	-33.185.717	-148.345.328	-246.055.582	-88.580.286	-65.840.492	-27.974.827	-31.993.724	7.488.433	-16.390.785
Forslag til udbytte	0	0	0	0	0	0	0	0	0

Aktiver

10.06.2024

Årsrapport	2023 10.06.2024	2022 26.05.2023	2021 03.06.2022	2020 06.07.2021	2019 12.05.2020	2018 30.05.2019	2017 29.05.2018	2016 04.05.2017	2015 18.05.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	65.918.363	3.091.089	57.652.809	13.128.461	9.010.895	10.724.108	13.636.766	10.954.737	5.620.381
Likvider	19.103.464	73.127.414	33.208.772	71.509.869	21.727.483	29.973.070	3.925.841	29.455.722	2.489.238
Kortfristede aktiver	85.021.827	117.500.193	90.861.581	84.638.331	30.738.378	40.697.178	17.562.607	40.410.459	8.109.619
Immaterielle aktiver og goodwill	3.315.789	4.500.000	4.500.000	4.500.000	0	0	0	0	0
Finansielle anlægsaktiver	2.335.626	0	183.646.388	0	949.972	2.950.881	4.617.806	1.180.278	1.263.841
Materielle aktiver	7.067.203	10.487.693	14.382.761	17.971.536	2.444.538	1.337.889	1.032.907	920.289	615.257
Langfristede aktiver	12.718.618	17.451.504	202.679.149	407.969.767	3.394.510	4.288.770	5.650.713	2.100.567	1.879.098
Aktiver	97.740.445	134.951.697	293.540.730	492.608.098	34.132.888	44.985.948	23.213.320	42.511.026	9.988.717

Aktiver

10.06.2024

Passiver

10.06.2024

Årsrapport	2023 10.06.2024	2022 26.05.2023	2021 03.06.2022	2020 06.07.2021	2019 12.05.2020	2018 30.05.2019	2017 29.05.2018	2016 04.05.2017	2015 18.05.2016
Forslag til udbytte	0	0	0	0	0	0	0	0	0
Egenkapital	84.303.311	115.372.809	261.741.125	458.250.112	7.773.841	-63.607.475	-36.731.624	-5.013.670	-12.667.782
Hensatte forpligtelser	0	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0	0
Anden langfristet gæld			7.270.404	12.747.605	520.178	0	0	0	0
Leverandører af varer og tjenesteydelser	5.093.993	8.861.679	15.961.187	11.109.571	21.424.245	5.263.829	3.937.499	4.837.199	2.119.524
Kortfristede forpligtelser	11.326.250	14.600.341	24.529.201	21.610.380	24.821.935	26.890.426	7.737.898	12.497.677	3.640.787
Gældsforpligtelser	13.437.134	19.578.888	31.799.605	34.357.986	26.359.047	108.593.423	59.944.944	47.524.696	22.656.499
Forpligtelser	13.437.134	19.578.888	31.799.605	34.357.986	26.359.047	108.593.423	59.944.944	47.524.696	22.656.499
Passiver	97.740.445	134.951.697	293.540.730	492.608.098	34.132.888	44.985.948	23.213.320	42.511.026	9.988.717

Passiver

10.06.2024

Nøgletal

10.06.2024

Årsrapport	2023 10.06.2024	2022 26.05.2023	2021 03.06.2022	2020 06.07.2021	2019 12.05.2020	2018 30.05.2019	2017 29.05.2018	2016 04.05.2017	2015 18.05.2016
Afkastningsgrad	-48,6 %	-51,6 %	-18,4 %	-16,1 %	-195,7 %	-76,0 %	-161,6 %	22,0 %	-207,9 %
Dækningsgrad	-183,3 %	Na.	Na.	Na.	Na.	Na.	-128,4 %	38,8 %	-75,9 %
Resultatgrad	-296,3 %	-1.493,6 %	-1.231,0 %	-1.522,3 %	-3.482,9 %	-70,8 %	-199,9 %	12,7 %	-150,7 %
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-39,4 %	-128,6 %	-94,0 %	-19,3 %	-846,9 %	44,0 %	87,1 %	-149,4 %	129,4 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-3.807,8 %	-707,7 %	-26,9 %	-164,3 %	-1.069,4 %	-2.326,0 %	Na.	Na.	Na.
Soliditestgrad	86,3 %	85,5 %	89,2 %	93,0 %	22,8 %	-141,4 %	-158,2 %	-11,8 %	-126,8 %
Likviditetsgrad	750,7 %	804,8 %	370,4 %	391,7 %	123,8 %	151,3 %	227,0 %	323,3 %	222,7 %

Resultat

10.06.2024

Gæld

10.06.2024

Årsrapport

10.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 10.06.2024)

Beretning

10.06.2024

Dato for ledelsens godkendelse af årsrapporten:2024-05-21

Ledelsespåtegning:Statement by Management on the annual report The Board of Directors and the Executive Board have today considered and approved the annual report of Saniona A/S for the financial year 01. 01. 2023 - 31. 12. 2023. The annual report is presented in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31. 12. 2023 and of the results of its operations for the financial year 01. 01. 2023 - 31. 12. 2023. We believe that the management commentary contains a fair review of the affairs and conditions referred to therein. We recommend the annual report for adoption at the Annual General Meeting.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:About Saniona Saniona is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona’s most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Bøhringer Ingelheim GmbH, Productos Medix, S. A de S. V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and the parent Company, Saniona AB is listed on Nasdaq Stockholm Main Market. For more information, please visit www. saniona. com.